CLINICAL TRIAL / NCT04586166

Inclusion Criteria: * At least 21 years of age * Vaginal bulge symptoms as indicated by an affirmative response of >1 to question 3 of the PFDI-SF20 * POP ≥ stage II according to the pelvic organ prolapse quantification (POP-Q) system45, with evidence of apical descent * Women being considered for minimally invasive sacrocolpopexy (with or without concomitant hysterectomy) * Objective SUI: positive standardized cough stress test on clinical examination or on urodynamic study with reduced prolapse * Understanding and acceptance of the need to return for all scheduled follow-up visits and willing to complete study questionnaires * Able to give informed consent Exclusion Criteria: * Prior surgery for stress urinary incontinence including mid-urethral sling; Burch/MMK; fascial pubovaginal sling (autologous, xenograft or allograft); and urethral bulking injection * Any serious disease, or chronic condition, that could interfere with the study compliance * Unwilling to have a synthetic sling * Untreated and unresolved urinary tract infection * Poorly-controlled diabetes mellitus (HgbA1c > 9 within 3 months of surgery date) * Neurogenic bladder/ pre-operative self-catheterization * Elevated post-void residual/PVR (>150 ml) that does not resolve with prolapse reduction testing (pessary, prolapse reduced uroflow or micturition study) * Prior pelvic radiation * Inflammatory bowel disease * Current genitourinary fistula or urethral diverticulum * Planned concomitant bowel related surgery including sphincteroplasty and perineal rectal prolapse surgery, rectovaginal fistula repair, hemorrhoidectomy * Pregnant or Planning to Conceive * Incarcerated